Fore Biotherapeutics Enters Pharma Business With BRAF Inhibitor as Lead Product

NEW YORK – Fore Biotherapeutics, which last month officially changed its name from NovellusDx, has transitioned to developing its own drugs and is advancing a targeted treatment for cancer patients with certain BRAF tumor mutations not addressed by available options.

To the publication →